Researchers have reported promising results from a study involving a new pill for advanced pancreatic cancer, raising hopes for improved treatments for this deadly disease. Dr. Zev Wainberg from UCLA stated that the drug, daraxonrasib, marks a significant advance even though it does not cure the cancer.
Daraxonrasib targets a mutated protein that promotes tumor growth in over 90% of pancreatic cancer cases. This protein has been a challenging target for treatment efforts over several decades. In a recent study, the drug almost doubled the survival time of patients, with fewer severe side effects compared to chemotherapy. The study included 500 patients with metastatic pancreatic cancer that had stopped responding to prior treatments. Results were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
Patients who took daraxonrasib had a median survival time of 13.2 months, compared to 6.7 months for those receiving chemotherapy. Dr. Rachna Shroff, a specialist not involved in the research, expressed emotional relief upon seeing the results. The treatment not only extended life but also improved patients’ quality of life, reducing pain as their tumors shrank.
Even though the drug’s effects eventually diminish, many patients continued using it longer than those on chemotherapy, suggesting the survival gap could increase over time. Dr. Brian Wolpin from the Dana-Farber Cancer Institute mentioned that this drug could become a new standard for treating metastatic pancreatic cancer. It may also be tested for use earlier in the disease’s progression.
Common side effects include a potentially severe rash and mouth sores, but these are manageable for many patients. The FDA is expediting the review of daraxonrasib, with expanded access available for patients meeting specific criteria. Former U.S. Sen. Ben Sasse shared his positive experience with the drug on “60 Minutes,” increasing interest among patients.
Pancreatic cancer remains one of the deadliest cancers due to late detection and few treatment options. The American Cancer Society projects about 67,000 new cases this year in the U.S., with over 52,000 deaths projected. The five-year survival rate stands at 13%. Unlike some other cancers, pancreatic cancer has limited effective chemotherapy alternatives.
The new medication targets KRAS gene mutations, crucial in pancreatic cancer progression. Traditionally considered unapproachable, Revolution Medicines’ molecular glue technology helps daraxonrasib to bind to various KRAS subtypes effectively. Dr. Andrew Coveler from the Fred Hutchinson Cancer Center highlighted its distinct action mechanism and its potential to change treatment strategies.
Ongoing research will investigate the effectiveness on different KRAS subtypes. Early tests of vaccines designed to prevent cancer recurrence by leveraging the immune system against mutated proteins are also underway. This development represents a step forward in the fight against pancreatic cancer.